Advaxis Appoints Ranya Dajani as Vice President, Corporate Development

PRINCETON, N.J., July 12, 2016 -- (Healthcare Sales &Marketing Network) -- Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Ranya Dajani joined Advaxis as Vice President, Corporate Development... Biopharmaceuticals, Oncology, PersonnelAdvaxis, Lm Technology, Listeria monocytogenes, immunotherapeutic
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract In the metastasis-targeted organs, angiogenesis is essential for the progression of dormant micrometastases to rapidly growing and clinically overt lesions. However, we observed changes suggesting angiogenic switching in the mouse lungs prior to arrival of tumor cells (i.e., in the premetastatic niche) in the models of breast carcinoma. This angiogenic switching appears to be caused by myeloid-derived suppressor cells recruited to the premetastatic lungs through complement C5a receptor 1 signaling. These myeloid cells are known to secrete several proangiogenic factors in tumors, including IL-1β and m...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
Listeria monocytogenes is a promising therapeutic vaccine vector for cancer immunotherapy. Although highly attenuated, three cases of systemic listeriosis have been reported in people following treatment with Lis...
Source: BMC Veterinary Research - Category: Veterinary Research Authors: Tags: Case Report Source Type: research
Abstract No immunotherapy strategy is yet offering consistent results against Pancreatic ductal adenocarcinoma (PDAC). A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients. PMID: 31315885 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsFor the first time, a listeria vaccine-based immunotherapy was shown to be able to induce a tumor antigen-specific T cell response within the tumor microenvironment of a “cold” tumor such as PDAC and sensitize the tumor to checkpoint inhibitor therapy. Moreover, this combination immunotherapy led to objective tumor responses and survival benefit in the mice with spontaneously developed PDAC tumors. Therefore, our study supports developing Lm-ANXA2 as a therapeut ic agent in combination with anti-PD-1 antibody for PDAC treatment.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Alessandro Poggi1*, Roberto Benelli2, Roberta Venè1, Delfina Costa1, Nicoletta Ferrari1, Francesca Tosetti1 and Maria Raffaella Zocchi3 1Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy 2Immunology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy 3Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy It is well established that natural killer (NK) cells are involved in both innate and adaptive immunity. Indeed, they can recognize molecules induced at the cell surface by stress signals ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
IL-12 Expands and Differentiates Human Vγ2Vδ2 T Effector Cells Producing Antimicrobial Cytokines and Inhibiting Intracellular Mycobacterial Growth Rui Yang1, Lan Yao1, Ling Shen2, Wei Sha1*, Robert L. Modlin3,4, Hongbo Shen1* and Zheng W. Chen2 1Shanghai Key Lab of Tuberculosis, Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, China2Department of Microbiology and Immunology, Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago, IL, United States3Department of Microbiol...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study also identified that the depletion of Langerin+CD8+ cDC1 resulted in diminished protective immune responses against intravenous Mycobacterium bovis infection. Langerin+CD8+ cDC1-depleted mice displayed increased bacterial loads, due to decreased IL-12 production in combination with delayed and diminished CD8+ T cell responses (77). Interestingly, although CD8+ T cell responses recovered over time, the bacterial load continued to increase and could not be controlled. This indicates that early immune priming effects by Langerin+CD8+ cDC1 are essential for the fate of the immune response (77), which was also found ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: These finding suggest that Poly-ICLC could be safely used for inducing transient innate immune responses in treated HIV+ subjects indicating promise as an adjuvant for HIV therapeutic vaccines. Trial Registration:, identifier: NCT02071095. Introduction Innate immune dysregulation during HIV infection hinders the formation of anti-HIV adaptive immunity (1–6) resulting in rampant viral dissemination and progression to AIDS. Adherence to combination anti-retroviral therapy (cART) regimens controls viremia, restores CD4+T cell counts and reverses immune dysfunction to a larg ext...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionReceipt of aL. monocytogenes-based vaccine is a novel risk factor for delayedL. monocytogenes bacteremia.
Source: Infection - Category: Infectious Diseases Source Type: research
Publication date: 17 July 2018Source: Cell Reports, Volume 24, Issue 3Author(s): Mayura V. Wagle, Julia M. Marchingo, Jason Howitt, Seong-Seng Tan, Christopher C. Goodnow, Ian A. ParishSummaryEscape from peripheral tolerance checkpoints that control cytotoxic CD8+ T cells is important for cancer immunotherapy and autoimmunity, but pathways enforcing these checkpoints are mostly uncharted. We reveal that the HECT-type ubiquitin ligase activator, NDFIP1, enforces a cell-intrinsic CD8+ T cell checkpoint that desensitizes TCR signaling during in vivo exposure to high antigen levels. Ndfip1-deficient OT-I CD8+ T&...
Source: Cell Reports - Category: Cytology Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Immunotherapy | Listeria | Marketing | Pharmaceuticals